Myeloid Therapeutics rebranded as Create Medicines and announced an expanded strategy to program multiple immune lineages in vivo using an mRNA‑LNP platform. The company said the pivot will add T cell and NK cell programming to its myeloid portfolio, aiming for scalable, redosable immunotherapies delivered directly in patients. CEO Daniel Getts outlined preclinical promise in partial responses and tumor microenvironment modulation and described plans for in‑vivo CAR programs targeting HER2, TROP2 and GPC3. The repositioning reflects a strategic effort to make cell programming therapeutics more manufacturable and accessible by avoiding ex vivo cell manufacturing.